CytomX Therapeutics Reports Q4 and Full-Year 2025 Financial Misses

Font: Financial Modeling Prep  • Mar 16, 2026

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Reports Q4 and Full-Year 2025 Results: Misses Estimates Amid Revenue Decline

• Earnings per share (EPS): Reported adjusted quarterly loss of -$0.22 per share, missing the Zacks Consensus Estimate of -$0.08 (earnings surprise: -175.00%). This compares to adjusted earnings of +$0.22 per share in the year-ago quarter.
• Revenue: $0.66 million (or $661,000), significantly below the Zacks Consensus Estimate. This continues a trend of revenue challenges, with prior quarter at ~$0.66 million (miss by ~91%).
• Financial health: Strong liquidity with a current ratio of 3.64 and low debt-to-equity ratio of 5.21% (total debt ~$5.6 million). However, negative operating cash flow contributes to a challenging enterprise value to operating cash flow profile (negative values common in biotech with burn rates).

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage biotechnology company developing masked, conditionally activated biologics (PROBODY® therapeutics) for cancer, announced its fourth quarter and full-year 2025 financial results on March 16, 2026, before market open, with a conference call at 8:00 a.m. ET (BMO).

For the quarter ended December 31, 2025, the company reported a quarterly adjusted loss of $0.22 per share (vs. Zacks estimate of -$0.08 loss) and revenue of $0.66 million (sharply down from $38.09 million in the year-ago quarter, primarily due to completion of major collaboration obligations, e.g., with Bristol Myers Squibb, and slower recognition from partners like Moderna, Astellas, and Regeneron).

Full-year 2025 revenue was $76.2 million (down ~44.8% from 2024's $138.1 million), with the company ending the year with $137.1 million in cash, cash equivalents, and investments, providing a runway into the second quarter of 2027. The company highlighted progress in its pipeline, including Varsetatug Masetecan (EpCAM PROBODY® ADC) and CX-801, with ongoing clinical data expected.

Despite the revenue headwinds from maturing collaborations, CytomX maintains a solid cash position and continues advancing its innovative conditionally activated therapies. Stock reacted positively post-release. For the latest details, refer to the company's IR site or filings.